Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 448

1.

Synergistic Cross-Talk of Hedgehog and Interleukin-6 Signaling Drives Growth of Basal Cell Carcinoma.

Sternberg C, Gruber W, Eberl M, Tesanovic S, Stadler M, Elmer DP, Schlederer M, Grund S, Roos S, Wolff F, Kaur S, Mangelberger D, Lehrach H, Hache H, Wierling C, Laimer J, Lackner P, Wiederstein M, Kasper M, Risch A, Petzelbauer P, Moriggl R, Kenner L, Aberger F.

Int J Cancer. 2018 Jul 10. doi: 10.1002/ijc.31724. [Epub ahead of print]

PMID:
29987839
2.

Safety and Efficacy of Nivolumab for Metastatic Renal Cell Carcinoma: Real-World Results From an Expanded Access Program.

De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program Group.

BJU Int. 2018 Jun 29. doi: 10.1111/bju.14461. [Epub ahead of print]

PMID:
29956884
3.

Clinical Trials Corner.

Agarwal PK, Sternberg CN.

Bladder Cancer. 2018 Apr 26;4(2):243-244. doi: 10.3233/BLC-189033. No abstract available.

4.

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung, Krivoshik A, Sternberg CN.

N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.

PMID:
29949494
5.

Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Armstrong AJ, Anand A, Edenbrandt L, Bondesson E, Bjartell A, Widmark A, Sternberg CN, Pili R, Tuvesson H, Nordle Ö, Carducci MA, Morris MJ.

JAMA Oncol. 2018 Jul 1;4(7):944-951. doi: 10.1001/jamaoncol.2018.1093.

PMID:
29799999
6.

The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.

Saad F, Sternberg CN, Mulders PFA, Niepel D, Tombal BF.

Cancer Treat Rev. 2018 May 3;68:25-37. doi: 10.1016/j.ctrv.2018.04.014. [Epub ahead of print] Review.

7.

Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.

Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn DI, Larkin J, Pal SK, Powles T, Ryan CW, Sternberg CN, Uzzo R, Choueiri TK, Bex A.

Eur Urol. 2018 May 18. pii: S0302-2838(18)30349-X. doi: 10.1016/j.eururo.2018.05.002. [Epub ahead of print] Review.

PMID:
29784193
8.

Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.

Procopio G, Prisciandaro M, Iacovelli R, Cortesi E, Fornarini G, Facchini G, Cartenì G, Sabbatini R, Del Bene G, Galli L, Caserta C, Multari AG, Bregni M, Massari F, Buti S, De Giorgi U, Zustovich F, Milella M, Calabrò F, Mancini ML, Tortora G, Vernieri C, Santini D, Sorarù M, Ricotta R, Masini C, Tucci M, Fedeli SL, Ortega C, Mecozzi A, Ratta R, Sternberg CN, Verzoni E.

Clin Genitourin Cancer. 2018 Apr 19. pii: S1558-7673(18)30084-3. doi: 10.1016/j.clgc.2018.03.014. [Epub ahead of print]

PMID:
29753637
9.

Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica.

Mahjoubi L, Cecchi F, Massard C, Calabro F, Gazzah A, Bahleda R, Jamme P, Gelli M, Goere D, Lacroix L, Adam J, Heukamp L, Trenta P, Hembrough T, Soria JC, Sternberg C, Ducreux M.

Tumori. 2018 Mar 1:300891618763215. doi: 10.1177/0300891618763215. [Epub ahead of print]

PMID:
29714649
10.

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.

Eur Urol. 2018 Apr 16. pii: S0302-2838(18)30246-X. doi: 10.1016/j.eururo.2018.03.028. [Epub ahead of print] Review.

PMID:
29673712
11.

Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.

Dos Santos Guimarães I, Ladislau-Magescky T, Tessarollo NG, Dos Santos DZ, Gimba ERP, Sternberg C, Silva IV, Rangel LBA.

Pharmacol Rep. 2018 Jun;70(3):409-417. doi: 10.1016/j.pharep.2017.11.007. Epub 2017 Nov 21.

PMID:
29627688
12.

Differential bacterial capture and transport preferences facilitate co-growth on dietary xylan in the human gut.

Leth ML, Ejby M, Workman C, Ewald DA, Pedersen SS, Sternberg C, Bahl MI, Licht TR, Aachmann FL, Westereng B, Abou Hachem M.

Nat Microbiol. 2018 May;3(5):570-580. doi: 10.1038/s41564-018-0132-8. Epub 2018 Apr 2.

PMID:
29610517
13.

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.

Vaughn DJ, Bellmunt J, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Li H, Perini RF, Bajorin DF, de Wit R.

J Clin Oncol. 2018 Jun 1;36(16):1579-1587. doi: 10.1200/JCO.2017.76.9562. Epub 2018 Mar 28.

PMID:
29590008
14.

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.

Molina AM, Hutson TE, Nosov D, Tomczak P, Lipatov O, Sternberg CN, Motzer R, Eisen T.

Eur J Cancer. 2018 May;94:87-94. doi: 10.1016/j.ejca.2018.02.009. Epub 2018 Mar 20.

15.

Targeting Hodgkin and Reed-Sternberg Cells with an Inhibitor of Heat-Shock Protein 90: Molecular Pathways of Response and Potential Mechanisms of Resistance.

Segges P, Corrêa S, Du Rocher B, Vera-Lozada G, Krsticevic F, Arce D, Sternberg C, Abdelhay E, Hassan R.

Int J Mol Sci. 2018 Mar 13;19(3). pii: E836. doi: 10.3390/ijms19030836.

16.

Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial.

Rathkopf DE, Beer TM, Loriot Y, Higano CS, Armstrong AJ, Sternberg CN, de Bono JS, Tombal B, Parli T, Bhattacharya S, Phung, Krivoshik A, Scher HI, Morris MJ.

JAMA Oncol. 2018 May 1;4(5):694-701. doi: 10.1001/jamaoncol.2017.5808.

17.

Clinical Trials Corner.

Agarwal PK, Sternberg CN.

Bladder Cancer. 2018 Jan 20;4(1):133-136. doi: 10.3233/BLC-189028. No abstract available.

18.

Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.

Gutjahr JC, Szenes E, Tschech L, Asslaber D, Schlederer M, Roos S, Yu X, Girbl T, Sternberg C, Egle A, Aberger F, Alon R, Kenner L, Greil R, Orian-Rousseau V, Hartmann TN.

Blood. 2018 Mar 22;131(12):1337-1349. doi: 10.1182/blood-2017-08-802462. Epub 2018 Jan 19.

19.

The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC).

Fernandes GS, Sternberg C, Lopes G, Chammas R, Gifoni MAC, Gil RA, Araujo DV.

Braz J Med Biol Res. 2018 Jan 11;51(3):e7214. doi: 10.1590/1414-431X20177214.

20.

Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma.

Sternberg CN, Donskov F, Haas NB, Doehn C, Russo P, Elmeliegy M, Baneyx G, Banerjee H, Aimone P, Motzer RJ.

Clin Cancer Res. 2018 Jul 1;24(13):3005-3013. doi: 10.1158/1078-0432.CCR-17-2652. Epub 2018 Jan 12.

PMID:
29330204
21.

Application of RNA-seq and Bioimaging Methods to Study Microbe-Microbe Interactions and Their Effects on Biofilm Formation and Gene Expression.

Amador CI, Sternberg C, Jelsbak L.

Methods Mol Biol. 2018;1734:131-158. doi: 10.1007/978-1-4939-7604-1_12.

PMID:
29288452
22.

Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis.

Santini D, Ratta R, Pantano F, De Lisi D, Maruzzo M, Galli L, Biasco E, Farnesi A, Buti S, Sternberg CN, Cerbone L, Di Lorenzo G, Spoto S, Sterpi M, De Giorgi U, Berardi R, Torniai M, Camerini A, Massari F, Procopio G, Tonini G.

Oncotarget. 2017 Aug 7;8(59):100708-100716. doi: 10.18632/oncotarget.20022. eCollection 2017 Nov 21.

23.

Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer.

de Almeida VH, de Melo AC, Meira DD, Pires AC, Nogueira-Rodrigues A, Pimenta-Inada HK, Alves FG, Moralez G, Thiago LS, Ferreira CG, Sternberg C.

Braz J Med Biol Res. 2017 Nov 13;51(1):e6822. doi: 10.1590/1414-431X20176822.

24.

Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.

Moschini M, Shariat SF, Rouprêt M, De Santis M, Bellmunt J, Sternberg CN, Tombal B, Collette L.

J Urol. 2018 May;199(5):1149-1157. doi: 10.1016/j.juro.2017.11.068. Epub 2017 Nov 20.

PMID:
29158104
25.

Clinical Trials Corner.

Agarwal PK, Sternberg CN.

Bladder Cancer. 2017 Oct 27;3(4):315-317. doi: 10.3233/BLC-179024. No abstract available.

26.

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.

Armstrong AJ, Antonarakis ES, Taplin ME, Kelly WK, Beltran H, Fizazi K, Dahut WL, Shore N, Slovin S, George D, Carducci MA, Corn P, Danila D, Dreicer R, Heath E, Rathkopf D, Liu G, Nanus D, Stein M, Smith MR, Sternberg C, Wilding G, Nelson PS, Halabi S, Kantoff P, Clarke NW, Evans CP, Heidenreich A, Mottet N, Gleave M, Morris MJ, Scher HI.

Ann Oncol. 2018 Jan 1;29(1):23-25. doi: 10.1093/annonc/mdx648. No abstract available.

PMID:
29088323
27.

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Bellmunt J, Galsky MD; RISC Investigators.

Ann Oncol. 2018 Feb 1;29(2):361-369. doi: 10.1093/annonc/mdx692.

PMID:
29077785
28.

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.

Fizazi K, Ulys A, Sengeløv L, Moe M, Ladoire S, Thiery-Vuillemin A, Flechon A, Guida A, Bellmunt J, Climent MA, Chowdhury S, Dumez H, Matouskova M, Penel N, Liutkauskiene S, Stachurski L, Sternberg CN, Baton F, Germann N, Daugaard G.

Ann Oncol. 2017 Nov 1;28(11):2741-2746. doi: 10.1093/annonc/mdx487.

PMID:
29059273
29.

Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance.

Gruber W, Peer E, Elmer DP, Sternberg C, Tesanovic S, Del Burgo P, Coni S, Canettieri G, Neureiter D, Bartz R, Kohlhof H, Vitt D, Aberger F.

Int J Cancer. 2018 Mar 1;142(5):968-975. doi: 10.1002/ijc.31117. Epub 2017 Nov 6.

30.

Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.

Bellmunt J, Eigl BJ, Senkus E, Loriot Y, Twardowski P, Castellano D, Blais N, Sridhar SS, Sternberg CN, Retz M, Pal S, Blumenstein B, Jacobs C, Stewart PS, Petrylak DP.

Ann Oncol. 2017 Oct 1;28(10):2481-2488. doi: 10.1093/annonc/mdx400.

PMID:
28961845
31.

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.

Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Fléchon A, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Géczi L, Ou YC, Coskun HS, Su WP, Hegemann M, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Del Muro XG, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T; RANGE study investigators.

Lancet. 2017 Nov 18;390(10109):2266-2277. doi: 10.1016/S0140-6736(17)32365-6. Epub 2017 Sep 12.

PMID:
28916371
32.

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Russo P, Sternberg CN; PROTECT investigators.

J Clin Oncol. 2017 Dec 10;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13.

PMID:
28902533
33.

Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer.

Pezaro CJ, Omlin A, Mastris K; ANZUP Consumer Advisory Panel, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS, Hussain M, James N, Logothetis CJ, Morgans A, Parker C, Ryan CJ, Saad F, Sartor O, Small EJ, Sternberg CN, Sweeney CJ, Tannock I, Tombal B, Gillessen S.

Ann Oncol. 2017 Aug 1;28(8):1692-1694. doi: 10.1093/annonc/mdx312. No abstract available.

PMID:
28838209
34.

Clinical Trials Corner.

Agarwal PK, Sternberg CN.

Bladder Cancer. 2017 Jul 27;3(3):229-230. doi: 10.3233/BLC-179022. No abstract available.

35.

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.

Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K; Young Academic Urologists-Urothelial Carcinoma Group-European Association of Urology and the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium group.

Eur Urol Focus. 2017 Jun 3. pii: S2405-4569(17)30125-6. doi: 10.1016/j.euf.2017.05.006. [Epub ahead of print]

PMID:
28753897
36.

Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.

Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD; Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Eur Urol Focus. 2017 Mar 31. pii: S2405-4569(17)30079-2. doi: 10.1016/j.euf.2017.03.011. [Epub ahead of print]

PMID:
28753879
37.

The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer.

van Soest RJ, Efstathiou JA, Sternberg CN, Tombal B.

Eur Urol Focus. 2016 Dec;2(5):480-487. doi: 10.1016/j.euf.2016.12.006. Epub 2017 Jan 6. Review.

PMID:
28723513
38.

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.

Zurita AJ, Gagnon RC, Liu Y, Tran HT, Figlin RA, Hutson TE, D'Amelio AM Jr, Sternberg CN, Pandite LN, Heymach JV.

Br J Cancer. 2017 Aug 8;117(4):478-484. doi: 10.1038/bjc.2017.206. Epub 2017 Jul 6.

PMID:
28683470
39.

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A.

Eur Urol. 2018 Feb;73(2):178-211. doi: 10.1016/j.eururo.2017.06.002. Epub 2017 Jun 24.

40.

Systemic chemotherapy in muscle invasive and metastatic bladder cancer: present and future.

Del Bene G, Sternberg CN.

Urologia. 2017 Aug 1;84(3):130-141. doi: 10.5301/uj.5000230. Epub 2017 Jun 14. Review.

PMID:
28623648
41.

Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation.

Bamias A, Escudier B, Sternberg CN, Zagouri F, Dellis A, Djavan B, Tzannis K, Kontovinis L, Stravodimos K, Papatsoris A, Mitropoulos D, Deliveliotis C, Dimopoulos MA, Constantinides CA.

Oncologist. 2017 Jun;22(6):667-679. doi: 10.1634/theoncologist.2016-0435. Epub 2017 Jun 7. Review.

42.

XAF1 expression levels in a non-small cell lung cancer cohort and its potential association with carcinogenesis.

Schluckebier L, Aran V, De Moraes J, Paiva H, Sternberg C, Ferreira CG.

Oncol Rep. 2017 Jul;38(1):402-410. doi: 10.3892/or.2017.5680. Epub 2017 May 30.

PMID:
28560416
43.

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.

Colomba E, Le Teuff G, Eisen T, Stewart GD, Fife K, Larkin J, Biondo A, Pickering L, Srinivasan A, Boyle H, Derosa L, Sternberg CN, Recine F, Ralph C, Saldana C, Barthélémy P, Bernhard JC, Gurney H, Verhoest G, Vauleon E, Bigot P, Berger J, Pfister C, Gravis G, Rodier JM, Culine S, Caty A, Rolland F, Priou F, Escudier B, Albiges L.

Eur J Cancer. 2017 Jul;80:55-62. doi: 10.1016/j.ejca.2017.03.011. Epub 2017 May 23.

PMID:
28549248
44.

Clinical Trials Corner.

Agarwal PK, Sternberg CN.

Bladder Cancer. 2017 Apr 27;3(2):141-142. doi: 10.3233/BLC-179016. No abstract available.

45.

An alert to Latin America: Current human papillomavirus vaccination trends highlight key barriers to successful implementation.

Nogueira-Rodrigues A, Bukowski A, Paulino E, St Louis J, Barrichello A, Sternberg C, Gifoni MAC, Luciani S, Goss PE.

Cancer. 2017 Jun 15;123(12):2193-2199. doi: 10.1002/cncr.30647. Epub 2017 Apr 25. No abstract available.

46.

Functional analysis of polymorphisms in the COX-2 gene and risk of lung cancer.

Moraes JL, Moraes AB, Aran V, Alves MR, Schluckbier L, Duarte M, Toscano E, Zamboni M, Sternberg C, de Moraes E, Lapa E Silva JR, Ferreira CG.

Mol Clin Oncol. 2017 Apr;6(4):494-502. doi: 10.3892/mco.2017.1167. Epub 2017 Feb 16.

47.

Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.

Alumkal JJ, Chowdhury S, Loriot Y, Sternberg CN, de Bono JS, Tombal B, Carles J, Flaig TW, Dorff TB, Phung, Forer D, Noonberg SB, Mansbach H, Beer TM, Higano CS.

Clin Genitourin Cancer. 2017 Oct;15(5):610-617.e3. doi: 10.1016/j.clgc.2017.02.007. Epub 2017 Mar 3.

PMID:
28344102
48.

A "miracle" cancer drug in the era of social media: A survey of Brazilian oncologists' opinions and experience with phosphoethanolamine.

Rêgo JF, Lopes G, Riechelmann RP, Sternberg C, Ferrari C, Fernandes G.

Rev Assoc Med Bras (1992). 2017 Jan 1;63(1):70-77. doi: 10.1590/1806-9282.63.01.70.

49.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators.

N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17.

50.

Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signaling.

Aberger F, Hutterer E, Sternberg C, Del Burgo PJ, Hartmann TN.

Cell Commun Signal. 2017 Jan 25;15(1):8. doi: 10.1186/s12964-017-0163-4. Review.

Supplemental Content

Loading ...
Support Center